Future Directions and Five-Year Outlook

Dr. Camidge predicts TROP2-directed ADCs will become obsolete due to poor tolerability profiles, while better-tolerated ADC platforms will emerge. He anticipates advances in understanding persistent cell populations preventing complete tumor eradication, potentially through surface marker-directed ADCs or radiopharmaceuticals. Pleural-based therapies represent another frontier, given recurrent pleural involvement in EGFR-mutant disease.

Dr. Rotow shares optimism about novel agents offering improved efficacy and tolerability. Understanding persistent cell populations that enable tumor dormancy for years before re-emergence represents the critical missing link for achieving durable responses. Consolidation therapy approaches using radiation, radiopharmaceuticals, or ADCs may help eliminate minimal residual disease and extend survival.

Dr. Devarakonda emphasizes learning appropriate treatment de-escalation for patients not requiring intensive therapy, balancing quality of life with survival benefits. Better biomarker dissection is needed, noting heterogeneity in control arm outcomes across studies may reflect patient selection differences or TP53 mutation complexity including gain-of-function versus loss-of-function variants.

Dr. Lopes identifies multiple priorities: expediting global drug approvals, particularly for agents approved in China; developing strategies to make EGFR tumors immunologically "hot"; advancing less toxic ADC payloads; exploring radiopharmaceuticals; and investigating microbiome manipulation for immunotherapy enhancement.

Dr. Levy adds emphasis on immunotherapy development despite EGFR-mutant disease traditionally being immunologically "cold," noting potential for cure through immune activation. He also highlights liquid biopsy dynamics for treatment decision-making based on plasma result changes rather than single timepoint measurements.

The discussion concludes with recognition that while significant advances have extended survival, achieving cure remains the ultimate goal requiring continued innovation across multiple therapeutic modalities.